Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The com...
Jun 24, 2025, 10:11 AM EDT - 2 days ago
Jun 12, 2025, 5:18 PM EDT - 14 days ago
May 27, 2025, 7:00 AM EDT - 4 weeks ago
IQV
May 19, 2025, 4:51 PM EDT - 5 weeks ago
May 15, 2025, 4:09 PM EDT - 6 weeks ago
May 12, 2025, 7:00 AM EDT - 6 weeks ago
May 1, 2025, 7:00 AM EDT - 2 months ago
Apr 30, 2025, 4:05 PM EDT - 2 months ago
Apr 28, 2025, 7:00 AM EDT - 2 months ago
Apr 23, 2025, 7:00 AM EDT - 2 months ago
Apr 15, 2025, 7:00 AM EDT - 2 months ago
Apr 7, 2025, 4:17 PM EDT - 2 months ago